nach oben

Die Gastroenterologie

Erschienen in:

26.02.2021 | Ultraschall | CME

Diabetes mellitus und Fettlebererkrankungen

verfasst von: Prof. Dr. Jörg Bojunga, Andreas Geier

Erschienen in: Die Gastroenterologie | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die nichtalkoholische Fettlebererkrankung (NAFLD) stellt eine häufige, aber oft unterschätze Komorbidität des Diabetes mellitus dar. Sie kann nicht nur Folge eines Diabetes sein, sondern diesem auch vorausgehen. Durch kardiovaskuläre, maligne und hepatische Komplikationen ist die NAFLD mit einer gesteigerten Morbidität und Mortalität verbunden. Patienten aus Risikogruppen sollten daher hinsichtlich einer NAFLD untersucht werden. Neben der Bestimmung der Steatose mittels Sonographie wird insbesondere eine Evaluation bezüglich des Vorliegens einer Leberfibrose anhand von Risikoscores empfohlen. Eine fortgeschrittene NAFLD geht mit einem erhöhten Risiko für ein hepatozelluläres Karzinom (HCC) einher, sodass ein entsprechendes Screening zu erwägen ist. Neben Allgemeinmaßnahmen zur Therapie einer Adipositas und einer Insulinresistenz können Antidiabetika, Statinen und Inhibitoren des Renin-Angiotensin-Systems sowie Azetylsalizylsäure einen günstigen Einfluss auf die NAFLD zeigen.

Roeb E, Steffen HM et al (2015) S2k Guideline non-alcoholic fatty liver disease. Z Gastroenterol 53(7):668–723PubMed

Dulai PS, Singh S et al (2017) Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology 65(5):1557–1565PubMedCrossRef

Geier A, Boursier J (2020) Non-invasive diagnosis of patients with “at-risk” NAFLD: only fibrosis counts? Gut 69(7):1164–1165PubMedCrossRef

Younossi ZM, Koenig AB et al (2016) Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64(1):73–84PubMedCrossRef

Jacobs E, Hoyer A et al (2017) Burden of mortality attributable to diagnosed diabetes: a nationwide analysis based on claims data from 65 million people in Germany. Diabetes Care 40(12):1703–1709PubMedCrossRef

Lonardo A, Nascimbeni F et al (2018) Hypertension, diabetes, atherosclerosis and NASH: cause or consequence? J Hepatol 68(2):335–352PubMedCrossRef

Fabiani S, Fallahi P et al (2018) Hepatitis C virus infection and development of type 2 diabetes mellitus: systematic review and meta-analysis of the literature. Rev Endocr Metab Disord 19(4):405–420PubMedCrossRef

Zein NN, Abdulkarim AS et al (2000) Prevalence of diabetes mellitus in patients with end-stage liver cirrhosis due to hepatitis C, alcohol, or cholestatic disease. J Hepatol 32(2):209–217PubMedCrossRef

Goldberg D, Ditah IC et al (2017) Changes in the prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation. Gastroenterology 152(5):1090–1099.e1PubMedCrossRef

10.

Wong VW‑S, Chitturi S et al (2016) Pathogenesis and novel treatment options for non-alcoholic steatohepatitis. Lancet Gastroenterol Hepatol 1(1):56–67PubMedCrossRef

11.

Weiß J, Rau M et al (2014) Nichtalkoholische fettlebererkrankung: Epidemiologie, verlauf, diagnostik und therapie. Dtsch Arztebl Int 111(26):447–452PubMedPubMedCentral

12.

Meex RCR, Watt MJ (2017) Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance. Nat Rev Endocrinol 13(9):509–520PubMedCrossRef

13.

Bedogni G, Bellentani S et al (2006) The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 6(1):33PubMedPubMedCentralCrossRef

14.

Zelber-Sagi S, Lotan R et al (2013) Non-alcoholic fatty liver disease independently predicts prediabetes during a 7-year prospective follow-up. Liver Int 33(9):1406–1412PubMedCrossRef

15.

Cai J, Zhang S et al (2015) Association between nonalcoholic fatty liver disease and carotid atherosclerosis: a meta-analysis. Int J Clin Exp Med 8(5):7673–7678PubMedPubMedCentral

16.

Friedrich-Rust M, Schoelzel F et al (2017) Severity of coronary artery disease is associated with non-alcoholic fatty liver disease: a single-blinded prospective mono-center study. PLoS One 12(10):e186720. https://doi.org/10.1371/journal.pone.0186720CrossRefPubMedPubMedCentral

17.

Ekstedt M, Hagström H et al (2015) Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61(5):1547–1554PubMedCrossRef

18.

Angulo P, Hui JM et al (2007) The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45(4):846–854PubMedCrossRef

19.

Sterling RK, Lissen E et al (2006) Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 43(6):1317–1325PubMedCrossRef

20.

Castera L, Friedrich-Rust M et al (2019) Non-invasive assessment of liver disease in patients with NAFLD. Gastroenterology 156(5):1264–1281.e4. https://doi.org/10.1053/j.gastro.2018.12.036CrossRefPubMed

21.

Tsilidis KK, Kasimis JC et al (2015) Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ 350:g7607PubMedCrossRef

22.

Simon TG, King LY et al (2018) Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: results from two prospective cohort studies. Hepatology 67(5):1797–1806PubMedCrossRef

23.

Kasmari AJ, Welch A et al (2017) Independent of cirrhosis, hepatocellular carcinoma risk is increased with diabetes and metabolic syndrome. Am J Med 130(6):746.e1–746.e7. https://doi.org/10.1016/j.amjmed.2016.12.029CrossRef

24.

George ES, Forsyth A et al (2018) Practical dietary recommendations for the prevention and management of nonalcoholic fatty liver disease in adults. Adv Nutr 9(1):30–40PubMedPubMedCentralCrossRef

25.

Ryan MC, Itsiopoulos C et al (2013) The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol 59(1):138–143PubMedCrossRef

26.

O’Donnell M, Mente A et al (2020) Salt and cardiovascular disease: insufficient evidence to recommend low sodium intake. Eur Heart J 41(35):3363–3373. https://doi.org/10.1093/eurheartj/ehaa586CrossRefPubMed

27.

Johannes S (2019) Kohlenhydratrestriktion bei Typ-2-Diabetes aus Sicht des Präventivmediziners. Diabetes aktuell 17(08):305–310CrossRef

28.

Parker HM, Johnson NA et al (2012) Omega‑3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 56(4):944–951PubMedCrossRef

29.

Ouyang X, Cirillo P et al (2008) Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol 48(6):993–999PubMedPubMedCentralCrossRef

30.

Romero-Gómez M, Zelber-Sagi S et al (2017) Treatment of NAFLD with diet, physical activity and exercise. J Hepatol 67(4):829–846PubMedCrossRef

31.

Molloy JW, Calcagno CJ et al (2012) Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology 55(2):429–436PubMedCrossRef

32.

Cosentino F, Grant PJ et al (2020) 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 41(2):255–323PubMedCrossRef

33.

Iranshahy M, Rezaee R et al (2019) Hepatoprotective activity of metformin: a new mission for an old drug? Eur J Pharmacol 850:1–7PubMedCrossRef

34.

Armstrong MJ, Hull D et al (2015) Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatophepatitis. J Hepatol 64(2):399–408PubMedCrossRef

35.

Liu L, Yan H et al (2020) Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes. Diabetes Metab Res Rev 36(5):e3292. https://doi.org/10.1002/dmrr.3292CrossRefPubMed

36.

Kuchay MS, Krishan S et al (2020) Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial). Diabetologia 63(11):2434–2445. https://doi.org/10.1007/s00125-020-05265-7CrossRefPubMed

37.

Armstrong MJ, Gaunt P et al (2015) Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387(10019):679–690PubMedCrossRef

38.

Petit J‑M, Vergès B (2017) GLP‑1 receptor agonists in NAFLD. Diabetes Metab 43:2S28–2S33PubMedCrossRef

39.

Eriksson JW, Lundkvist P et al (2018) Effects of dapagliflozin and n‑3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. Diabetologia 61(9):1923–1934PubMedPubMedCentralCrossRef

40.

Kahl S, Gancheva S et al (2020) Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: A randomized, double-blind, phase 4, placebo-controlled trial. Diabetes Care 43(2):298–305PubMedCrossRef

41.

Salpeter S, Greyber E et al (2003) Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 1:CD2967

42.

Pose E, Trebicka J et al (2019) Statins: old drugs as new therapy for liver diseases? J Hepatol 70(1):194–202PubMedCrossRef

43.

Kim G, Jang S‑Y et al (2018) Statin use and the risk of hepatocellular carcinoma in patients at high risk: a nationwide nested case-control study. J Hepatol 68(3):476–484. https://doi.org/10.1016/j.jhep.2017.10.018CrossRefPubMed

44.

Del Ben M, Baratta F et al (2017) Under-prescription of statins in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 27(2):161–167PubMedCrossRef

45.

Pastori D, Polimeni L et al (2015) The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis 47(1):4–11PubMedCrossRef

46.

Hirose A, Ono M et al (2007) Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology 45(6):1375–1381PubMedCrossRef

47.

Schwarzkopf K, Bojunga J et al (2018) Use of antiplatelet agents is inversely associated with liver fibrosis in patients with cardiovascular disease. Hepatol Commun 2(12):1601–1609PubMedPubMedCentralCrossRef

48.

Simon TG, Ma Y et al (2018) Association between aspirin use and risk of hepatocellular carcinoma. JAMA Oncol 4(12):1683PubMedPubMedCentralCrossRef

Titel: Diabetes mellitus und Fettlebererkrankungen
verfasst von: Prof. Dr. Jörg Bojunga
Andreas Geier
Publikationsdatum: 26.02.2021
Verlag: Springer Medizin
Schlagwörter: Ultraschall
Hepatozelluläres Karzinom
Leberzirrhose
Fettleber
Hepatozelluläres Karzinom
Metformin
Statine
Diabetes mellitus
Ultraschall
Erschienen in: Die Gastroenterologie / Ausgabe 2/2021
Print ISSN: 2731-7420
Elektronische ISSN: 2731-7439
DOI: https://doi.org/10.1007/s11377-021-00510-w

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2021

Mitteilungen der NDGG

Mitteilungen des BDI

Mitteilungen der Gesellschaft für Gastroenterologie in NRW

Nichtzirrhotische portale Hypertension – Ursachen und praktisches Management

Mitteilungen des Netzwerks gegen Darmkrebs

Ischämische Enterokolitis – erkennen, diagnostizieren und behandeln